{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:45Z","timestamp":1791237825819,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-112-197"],"award-info":[{"award-number":["DMR-112-197"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2628-B-039-005"],"award-info":[{"award-number":["MOST110-2628-B-039-005"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST110-2314-B-039-032"],"award-info":[{"award-number":["MOST110-2314-B-039-032"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Colorectal cancer (CRC) ranks among the most commonly diagnosed cancers globally and is characterized by high mortality rates and significant intertumoral heterogeneity driven by somatic mutations and an immunosuppressive tumor microenvironment (TME). Despite the success of immune checkpoint blockers (ICBs) in various malignancies, the immunosuppressive TME limits their therapeutic efficacy in the majority of CRC patients. Therefore, strategies to unleash antitumor immunity are imperative to increase the therapeutic outcomes of these patients. ARID1A mutation is frequently observed in cancers and is known to be associated with tumor activity and poor prognosis, such as colorectal cancer. Additionally, ARID1A deficiency is associated with a reduced mismatch repair capacity, increased cancer mutability, and increased infiltration of immune cells, thus potentiating the efficacy of ICBs. In this study, we revealed that ARID1A regulates CHK1 protein stability through DDB1-mediated ubiquitination. ARID1A deficiency results in CHK1 upregulation and cytosolic single-strand DNA (ssDNA) accumulation. Targeting the ATR\/CHK1 axis triggers cancer cell-intrinsic innate immunity via the STING-mediated DNA-sensing pathway, thereby enhancing the therapeutic efficacy of radiotherapy (RT) and ICBs in ARID1A-deficient tumors. Taken together, these findings suggest that targeting the CHK1 checkpoint may serve as a therapeutic strategy to remodel the TME and enhance the response to radiotherapy and ICBs in ARID1A-deficient CRC.<\/jats:p>","DOI":"10.1038\/s41419-025-07912-6","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:13:34Z","timestamp":1754064814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Jhen-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao-Wei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ze","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-An","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Tzu-Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-2566","authenticated-orcid":false,"given":"K. S. Clifford","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-3233","authenticated-orcid":false,"given":"Kevin Chih-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"7912_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"7912_CR2","doi-asserted-by":"publisher","first-page":"a026930","DOI":"10.1101\/cshperspect.a026930","volume":"6","author":"C Hodges","year":"2016","unstructured":"Hodges C, Kirkland JG, Crabtree GR. The many roles of BAF (mSWI\/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med. 2016;6:a026930","journal-title":"Cold Spring Harb Perspect Med"},{"key":"7912_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor?. Cancer Discov. 2013;3:35\u201343.","journal-title":"Cancer Discov"},{"key":"7912_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10020-022-00469-6","volume":"28","author":"S Zhao","year":"2022","unstructured":"Zhao S, Wu W, Jiang Z, Tang F, Ding L, Xu W, et al. Roles of ARID1A variations in colorectal cancer: a collaborative review. Mol Med. 2022;28:42.","journal-title":"Mol Med"},{"key":"7912_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.21873\/invivo.11493","volume":"33","author":"JH Lee","year":"2019","unstructured":"Lee JH, Ahn BK, Baik SS, Lee KH. Comprehensive analysis of somatic mutations in colorectal cancer with peritoneal metastasis. In Vivo. 2019;33:447\u201352.","journal-title":"In Vivo"},{"key":"7912_CR6","doi-asserted-by":"publisher","first-page":"18404","DOI":"10.3748\/wjg.v20.i48.18404","volume":"20","author":"XL Wei","year":"2014","unstructured":"Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol. 2014;20:18404\u201312.","journal-title":"World J Gastroenterol"},{"key":"7912_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejca.2020.09.006","volume":"140","author":"R Tokunaga","year":"2020","unstructured":"Tokunaga R, Xiu J, Goldberg RM, Philip PA, Seeber A, Battaglin F, et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. Eur J Cancer. 2020;140:119\u201329.","journal-title":"Eur J Cancer"},{"key":"7912_CR8","doi-asserted-by":"publisher","first-page":"679334","DOI":"10.3389\/fonc.2021.679334","volume":"11","author":"S Baldi","year":"2021","unstructured":"Baldi S, Khamgan H, Qian Y, Wu H, Zhang Z, Zhang M, et al. Downregulated ARID1A by miR-185 is associated with poor prognosis and adverse outcomes in colon adenocarcinoma. Front Oncol. 2021;11:679334.","journal-title":"Front Oncol"},{"key":"7912_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06751-1","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhang X, Luo Y, Song Y, Xiang C, He Y, et al. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (reactivating p53 and inducing tumor apoptosis). Cell Death Dis. 2024;15:375.","journal-title":"Cell Death Dis"},{"key":"7912_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-022-00856-5","volume":"29","author":"J Mandal","year":"2022","unstructured":"Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biomed Sci. 2022;29:71.","journal-title":"J Biomed Sci"},{"key":"7912_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999626","volume":"12","author":"S Xu","year":"2022","unstructured":"Xu S, Sak A, Niedermaier B, Erol YB, Groneberg M, Mladenov E, et al. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. Front Oncol. 2022;12:999626.","journal-title":"Front Oncol"},{"key":"7912_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5:752\u201367.","journal-title":"Cancer Discov"},{"key":"7912_CR13","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.1600-0463.2012.02930.x","volume":"120","author":"MS Kim","year":"2012","unstructured":"Kim MS, Je EM, Yoo NJ, Lee SH. Loss of ARID1A expression is uncommon in gastric, colorectal, and prostate cancers. APMIS. 2012;120:1020\u20132.","journal-title":"APMIS"},{"key":"7912_CR14","doi-asserted-by":"crossref","unstructured":"Zhang L, Zheng Y, Chien W, Ziman B, Billet S, Koeffler HP, et al. ARID1A deficiency regulates anti-tumor immune response in esophageal adenocarcinoma. Cancers (Basel). 2023;15:5377.","DOI":"10.3390\/cancers15225377"},{"key":"7912_CR15","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ijc.32140","volume":"145","author":"YB Kim","year":"2019","unstructured":"Kim YB, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145:916\u201326.","journal-title":"Int J Cancer"},{"key":"7912_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/cac2.12465","volume":"43","author":"XY Chen","year":"2023","unstructured":"Chen XY, Li B, Wang Y, Jin J, Yang Y, Huang LH, et al. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Cancer Commun (Lond). 2023;43:1003\u201326.","journal-title":"Cancer Commun (Lond)"},{"key":"7912_CR17","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","volume":"21","author":"H Zhao","year":"2001","unstructured":"Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 2001;21:4129\u201339.","journal-title":"Mol Cell Biol"},{"key":"7912_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646\u201361.","journal-title":"Cancer Discov"},{"key":"7912_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/mc.23275","volume":"60","author":"R Chaudhary","year":"2021","unstructured":"Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, et al. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinog. 2021;60:138\u201350.","journal-title":"Mol Carcinog"},{"key":"7912_CR20","doi-asserted-by":"publisher","first-page":"828657","DOI":"10.3389\/fcell.2021.828657","volume":"9","author":"R Shen","year":"2021","unstructured":"Shen R, Liu D, Wang X, Guo Z, Sun H, Song Y, et al. DNA damage and activation of cGAS\/STING pathway induce tumor microenvironment remodeling. Front Cell Dev Biol. 2021;9:828657.","journal-title":"Front Cell Dev Biol"},{"key":"7912_CR21","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1172\/JCI130445","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, et al. Inhibition of the ATM\/Chk2 axis promotes cGAS\/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020;130:5951\u201366.","journal-title":"J Clin Invest"},{"key":"7912_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215795","volume":"543","author":"TW Chen","year":"2022","unstructured":"Chen TW, Hung WZ, Chiang SF, Chen WT, Ke TW, Liang JA, et al. Dual inhibition of TGFbeta signaling and CSF1\/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. Cancer Lett. 2022;543:215795.","journal-title":"Cancer Lett"},{"key":"7912_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01132-x","volume":"10","author":"TW Ke","year":"2025","unstructured":"Ke TW, Chen CY, Chen WT, Tsai YY, Chiang SF, Huang CH, et al. Targeting B7-H3 enhances the efficacy of neoantigen-based cancer vaccine in combination with radiotherapy. NPJ Vaccines. 2025;10:80.","journal-title":"NPJ Vaccines"},{"key":"7912_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06408-5","volume":"15","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chiang SF, Lin PC, Hong WZ, Yang PC, Chang HP, et al. TNFalpha modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer. Cell Death Dis. 2024;15:24.","journal-title":"Cell Death Dis"},{"key":"7912_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1989790","volume":"10","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Ke TW, Chen TW, Hu CH, Yang PC, et al. DNMT1 constrains IFNbeta-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. Oncoimmunology. 2021;10:1989790.","journal-title":"Oncoimmunology"},{"key":"7912_CR26","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00262-023-03416-4","volume":"72","author":"YS Lin","year":"2023","unstructured":"Lin YS, Chiang SF, Chen CY, Hong WZ, Chen TW, Chen WT, et al. Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation. Cancer Immunol Immunother. 2023;72:2283\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"7912_CR27","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1002\/jcp.30323","volume":"236","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Yang PC, Ke TW, Chen TW, Lin CY, et al. ATAD3A stabilizes GRP78 to suppress ER stress for acquired chemoresistance in colorectal cancer. J Cell Physiol. 2021;236:6481\u201395.","journal-title":"J Cell Physiol"},{"key":"7912_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-2109-5","volume":"67","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chiang SF, Ke TW, Chen TW, Lan YC, You YS, et al. Cytosolic high-mobility group box protein 1 (HMGB1) and\/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. Cancer Immunol Immunother. 2018;67:551\u201362.","journal-title":"Cancer Immunol Immunother"},{"key":"7912_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7603\/s40681-015-0005-x","volume":"5","author":"TY Lin","year":"2015","unstructured":"Lin TY, Fan CW, Maa MC, Leu TH. Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation. Biomedicine (Taipei). 2015;5:5.","journal-title":"Biomedicine (Taipei)"},{"key":"7912_CR30","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/cancers12020462","volume":"12","author":"KC Huang","year":"2020","unstructured":"Huang KC, Chiang SF, Chen WT, Chen TW, Hu CH, Yang PC, et al. Decitabine augments chemotherapy-Induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer. Cancers (Basel). 2020;12:462.","journal-title":"Cancers (Basel)"},{"key":"7912_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46254-1","volume":"13","author":"KC Huang","year":"2023","unstructured":"Huang KC, Ke TW, Chen JY, Hong WZ, Chiang SF, Lai CY, et al. Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. Sci Rep. 2023;13:19440.","journal-title":"Sci Rep"},{"key":"7912_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00881-5","volume":"9","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chen WT, Chen JY, Lee CY, Wu CH, Lai CY, et al. Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers. NPJ Vaccines. 2024;9:95.","journal-title":"NPJ Vaccines"},{"key":"7912_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116958","volume":"177","author":"KC Huang","year":"2024","unstructured":"Huang KC, Ke TW, Lai CY, Hong WZ, Chang HY, Lee CY, et al. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy. Biomed Pharmacother. 2024;177:116958.","journal-title":"Biomed Pharmacother"},{"key":"7912_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/2326-6066.CIR-22-0318","volume":"11","author":"KC Huang","year":"2023","unstructured":"Huang KC, Lai CY, Hung WZ, Chang HY, Lin PC, Chiang SF, et al. A novel engineered AAV-based neoantigen vaccine in combination with radiotherapy eradicates tumors. Cancer Immunol Res. 2023;11:123\u201336.","journal-title":"Cancer Immunol Res"},{"key":"7912_CR35","doi-asserted-by":"publisher","first-page":"e008515","DOI":"10.1136\/jitc-2023-008515","volume":"12","author":"KC Huang","year":"2024","unstructured":"Huang KC, Chiang SF, Chang HY, Hong WZ, Chen JY, Lee PC, et al. Colorectal cancer-specific IFNbeta delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy. J Immunother Cancer. 2024;12:e008515.","journal-title":"J Immunother Cancer"},{"key":"7912_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00262-024-03692-8","volume":"73","author":"JY Chen","year":"2024","unstructured":"Chen JY, Lin PY, Hong WZ, Yang PC, Chiang SF, Chang HY, et al. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy. Cancer Immunol Immunother. 2024;73:92.","journal-title":"Cancer Immunol Immunother"},{"key":"7912_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33927-5","volume":"8","author":"CY Huang","year":"2018","unstructured":"Huang CY, Chiang SF, Ke TW, Chen TW, You YS, Chen WT, et al. Clinical significance of programmed death 1 ligand-1 (CD274\/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Sci Rep. 2018;8:15658.","journal-title":"Sci Rep"},{"key":"7912_CR38","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.7150\/jca.91089","volume":"15","author":"LC Chen","year":"2024","unstructured":"Chen LC, Yang PC, Chen CY, Chiang SF, Chen TW, Chen WT, et al. Dual Inhibition of B7-H3 and EGFR overcomes acquired chemoresistance in colon adenocarcinoma. J Cancer. 2024;15:1750\u201361.","journal-title":"J Cancer"},{"key":"7912_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79419-3","volume":"10","author":"KC Huang","year":"2020","unstructured":"Huang KC, Chiang SF, Chen TW, Chen WT, Yang PC, Ke TW, et al. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2\/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Sci Rep. 2020;10:22330.","journal-title":"Sci Rep"},{"key":"7912_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1051\/bmdcn\/2018080104","volume":"8","author":"X Wang","year":"2018","unstructured":"Wang X, Sheu JJ, Lai MT, Yin-Yi Chang C, Sheng X, Wei L, et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. Biomedicine (Taipei). 2018;8:4.","journal-title":"Biomedicine (Taipei)"},{"key":"7912_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.CAN-18-2446","volume":"80","author":"Q Luo","year":"2020","unstructured":"Luo Q, Wu X, Chang W, Zhao P, Zhu X, Chen H, et al. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression. Cancer Res. 2020;80:406\u201317.","journal-title":"Cancer Res"},{"key":"7912_CR42","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-18-4222","volume":"25","author":"Y Park","year":"2019","unstructured":"Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25:5584\u201394.","journal-title":"Clin Cancer Res"},{"key":"7912_CR43","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ijc.30373","volume":"140","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017;140:109\u201319.","journal-title":"Int J Cancer"},{"key":"7912_CR44","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-12-1322","volume":"18","author":"MI Walton","year":"2012","unstructured":"Walton MI, Eve PD, Hayes A, Valenti MR, De Haven Brandon AK, Box G, et al. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res. 2012;18:5650\u201361.","journal-title":"Clin Cancer Res"},{"key":"7912_CR45","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/cb100428c","volume":"6","author":"F Huang","year":"2011","unstructured":"Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011;6:628\u201335.","journal-title":"ACS Chem Biol"},{"key":"7912_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2020.09.016","volume":"497","author":"F Neizer-Ashun","year":"2021","unstructured":"Neizer-Ashun F, Bhattacharya R. Reality CHEK: Understanding the biology and clinical potential of CHK1. Cancer Lett. 2021;497:202\u201311.","journal-title":"Cancer Lett"},{"key":"7912_CR47","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1158\/0008-5472.CAN-08-3382","volume":"69","author":"V Leung-Pineda","year":"2009","unstructured":"Leung-Pineda V, Huh J, Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 2009;69:2630\u20137.","journal-title":"Cancer Res"},{"key":"7912_CR48","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/febs.15132","volume":"287","author":"KB Cassidy","year":"2020","unstructured":"Cassidy KB, Bang S, Kurokawa M, Gerber SA. Direct regulation of Chk1 protein stability by E3 ubiquitin ligase HUWE1. FEBS J. 2020;287:1985\u201399.","journal-title":"FEBS J"},{"key":"7912_CR49","doi-asserted-by":"publisher","first-page":"13660","DOI":"10.1073\/pnas.1007856107","volume":"107","author":"JH Choi","year":"2010","unstructured":"Choi JH, Lindsey-Boltz LA, Kemp M, Mason AC, Wold MS, Sancar A. Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling. Proc Natl Acad Sci USA. 2010;107:13660\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7912_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana B, Gallerani G, Salamon I, Pace I, Roncarati R, Ferracin M. ARID1A in cancer: Friend or foe?. Front Oncol. 2023;13:1136248.","journal-title":"Front Oncol"},{"key":"7912_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6706-x","volume":"20","author":"M Erfani","year":"2020","unstructured":"Erfani M, Hosseini SV, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, et al. Altered ARID1A expression in colorectal cancer. BMC Cancer. 2020;20:350.","journal-title":"BMC Cancer"},{"key":"7912_CR52","doi-asserted-by":"publisher","first-page":"e53931","DOI":"10.1371\/journal.pone.0053931","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS One. 2013;8:e53931.","journal-title":"PLoS One"},{"key":"7912_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cas.16052","volume":"115","author":"R Huang","year":"2024","unstructured":"Huang R, Wu D, Zhang K, Hu G, Liu Y, Jiang Y, et al. ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance. Cancer Sci. 2024;115:439\u201351.","journal-title":"Cancer Sci"},{"key":"7912_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33172-5","volume":"13","author":"RM Johnson","year":"2022","unstructured":"Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, et al. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nat Commun. 2022;13:5478.","journal-title":"Nat Commun"},{"key":"7912_CR55","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24:556\u201362.","journal-title":"Nat Med"},{"key":"7912_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"key":"7912_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.648687","volume":"11","author":"W Sun","year":"2021","unstructured":"Sun W, Zhang Q, Wang R, Li Y, Sun Y, Yang L. Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications. Front Oncol. 2021;11:648687.","journal-title":"Front Oncol"},{"key":"7912_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36878-2","volume":"14","author":"C Dmello","year":"2023","unstructured":"Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, et al. Checkpoint kinase 1\/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun. 2023;14:1566.","journal-title":"Nat Commun"},{"key":"7912_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe6201","volume":"13","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pilie PG, Dai H, Lam TNA, Liang Y, Voorwerk L, et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Sci Transl Med. 2021;13:eabe6201.","journal-title":"Sci Transl Med"},{"key":"7912_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12037-4","volume":"10","author":"B Zhao","year":"2019","unstructured":"Zhao B, Lin J, Rong L, Wu S, Deng Z, Fatkhutdinov N, et al. ARID1A promotes genomic stability through protecting telomere cohesion. Nat Commun. 2019;10:4067.","journal-title":"Nat Commun"},{"key":"7912_CR61","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/genes10110868","volume":"10","author":"S Morimoto","year":"2019","unstructured":"Morimoto S, Tsuda M, Bunch H, Sasanuma H, Austin C, Takeda S. Type II DNA topoisomerases cause spontaneous double-strand breaks in genomic DNA. Genes (Basel). 2019;10:868.","journal-title":"Genes (Basel)"},{"key":"7912_CR62","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1172\/JCI127471","volume":"129","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Investig. 2019;129:4850\u201362.","journal-title":"J Clin Investig"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07912-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:52:46Z","timestamp":1757335966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7912"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07912-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with the relevant ethical guidelines and regulations. Tissue collection was approved by the Institutional Review Board (IRB) of China Medical University Hospital [Protocol number: CMUH107-REC2-008]. The animal care and experimental procedures were approved by the China Medical University Animal Care Committee (CMUIACUC-2018-182). Efforts were made to minimize animal suffering and reduce the number of animals used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all human participants or their legal guardians in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"584"}}